OncoMed Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OncoMed Pharmaceuticals, Inc.
Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.
J.P. Morgan Day Two: Playing Up Potential In The Year Ahead
Daily notebook from the J.P. Morgan Healthcare Conference: Small and mid-size companies take the stage to lay out their guidance for the year, while big pharma is pushed on strategy and business development. Updates from GSK, Mirati, Sarepta, Amgen and US FDA commissioner Robert Califf.
Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.